Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Jing-Jin Electric Technologies
688280
5
Hangzhou Anysoft Information Technology
300571
US OptionsDetailed Quotes
ANNX250516P5000
- 0.00
- 0.000.00%
15min DelayClose Apr 28 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover381.17%IV-164.55%PremiumMay 16, 2025Expiry Date3.11Intrinsic Value100Multiplier17DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7714Delta0.1930Gamma0.58Leverage Ratio-0.0131Theta-0.0017Rho-0.45Eff Leverage0.0013Vega
Annexon Newsroom
Express News | Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Jefferies Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $10
Annexon Biosciences' ANX005: Promising Phase III Results and Strategic Initiatives Drive Buy Rating
Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors
Annexon Says Tanruprubart Met The Primary Endpoint
Express News | Annexon Shares Are Trading Higher After the Company Announced the Presentation of Data for Its Late-stage Targeted Therapy for GBS at the AAN Annual Meeting
Reported Earlier, Annexon Spotlights First-in-Class ANX005 Phase 3 Results For GBS And Launches 'Move GBS Forward' Initiative At AAN
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
We're Not Very Worried About Annexon's (NASDAQ:ANNX) Cash Burn Rate
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
$ANNX Stock Is up 13% Today. Here's What We See in Our Data.
12 Health Care Stocks Moving In Monday's Pre-Market Session
BofA Securities Maintains Annexon(ANNX.US) With Buy Rating
Bank of America Securities Remains a Buy on Annexon Biosciences (ANNX)
TD Cowen Maintains Annexon(ANNX.US) With Buy Rating
Guillain-Barré Syndrome (GBS) Drug Development Pipeline Research Report 2025 Featuring Annexon and Hansa Biopharma
Jefferies Maintains Annexon(ANNX.US) With Buy Rating, Raises Target Price to $10
Promising Developments in Annexon Biosciences' Pipeline Drive Buy Rating
H.C. Wainwright Maintains Annexon(ANNX.US) With Buy Rating, Cuts Target Price to $20
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call